Atlas Trials

A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma

Clinical trial NCT07497373 · COMPLETED

Trial details

NCT number
NCT07497373
Sponsor
Jecho Biopharmaceuticals Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Glioblastoma Multiforme(GBM)
Start date
2022-11-16
Primary completion
2024-05-23
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.